Diphenhydramine Hydrochloride
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Diphenhydramine Hydrochloride
- Diphenhydramine Hydrochloride: Preliminary Assessment — Insufficient Data for Repurposing Evaluation
Diphenhydramine Hydrochloride: Preliminary Assessment — Insufficient Data for Repurposing Evaluation
One-Sentence Summary
Diphenhydramine Hydrochloride is a first-generation H1 antihistamine, widely recognised for its use in allergic conditions, insomnia, and motion sickness. No new indications were predicted by the TxGNN model in this Evidence Pack, and no SAHPRA registrations were identified in the current dataset. A full repurposing evaluation cannot proceed until prediction data and regulatory information are obtained.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, urticaria, insomnia, motion sickness (general drug knowledge; no SAHPRA-licensed indication in dataset) |
| Predicted New Indication | None — no TxGNN predictions present in this Evidence Pack |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction data absent; no linked studies |
| South Africa Market Status | Not Marketed (per current dataset) |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
South Africa Market Information
No SAHPRA registrations were found for Diphenhydramine Hydrochloride in the current dataset.
Note for reviewers: Diphenhydramine is a long-established OTC antihistamine globally. It may appear in South Africa under brand or combination product registrations (e.g., sleep aids, cough-and-cold preparations) that are not captured in this dataset. Manual verification via the SAHPRA medicines register is strongly recommended before concluding the drug is absent from the local market.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA via the MedSafety reporting portal.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack contains no TxGNN repurposing predictions, no SAHPRA registration data, no mechanism of action, and no safety information — making it impossible to conduct a meaningful repurposing evaluation at this stage.
To proceed, the following is needed:
- TxGNN output: Re-run the prediction pipeline with a valid DrugBank ID for Diphenhydramine Hydrochloride (DrugBank: DB01075) to generate repurposing candidates and confidence scores
- Mechanism of action (MOA): Query DrugBank API for pharmacological target and pathway data
- SAHPRA registration verification: Manually search the SAHPRA medicines register for Diphenhydramine-containing products, including combination formulations
- Professional Information (PI) / Package Insert: Retrieve from SAHPRA or the originator company to populate key warnings and contraindications
- Evidence collection: Once a predicted indication is identified, run ClinicalTrials.gov and PubMed collectors to populate clinical trial and literature evidence tables
This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application. Data as of 2026-04-20.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.